So-Young International Inc. (SY) Q4 2025 Earnings Call Transcript

So-Young held its Q4 2025 earnings call on Mar 25, 2026, highlighting progress on scale breakthroughs and operational improvements in its aesthetic center business and efforts to reinforce medical services. Management said China's medical aesthetic industry is undergoing structural adjustments with consumers becoming more value-driven and framed the company's investments as positioning for long-term edge in scalable, repeatable models.

Analysis

Consolidation in China's medical-aesthetic sector favors operators that can standardize clinical quality and unit economics; a leader that scales can drive CAC down ~20–30% and lift clinic-level EBITDA by 300–500bps within 12–18 months through centralized procurement, training, and scheduling optimization. That dynamic creates nonlinear advantages: each incremental center not only adds revenue but dilutes fixed compliance and physician training costs, making share gains stickier than headline revenue growth implies.

Second-order winners include injectable and device suppliers that gain volume (AbbVie, JNJ) and franchise/real-estate landlords who capture longer lease tenors and higher in-center footfall; losers are dispersed mom-and-pop clinics that face margin compression of 5–15% from price competition and rising compliance costs. Payment/financing partners and standardized training vendors will see demand growth ahead of clinical volumes, creating entry points for B2B services with SaaS-like margins within 2–3 years.

Key risks are regulatory or safety shocks that can roll back consumer confidence in weeks and trigger inspections that compress utilization for quarters, and macro-driven discretionary spending drops that knock 10–25% off average ticket size in bad months. Monitoring short-term leading indicators—appointment conversion rates, average ticket per procedure, and supplier order cadence—gives 4–12 week visibility into revenue/volume inflection points, while margin expansion is a 6–18 month call tied to network effects and procurement scale.

A practical valuation lever: if scalable operators can prove mid-single-digit market share gains nationally, enterprise value should re-rate as a consolidated healthcare-services multiple (10–14x FY+1 EBITDA) versus a fragmented consumer multiple; absent that proof, investor appetite will flip quickly to cashflow conservatism.

Key Decisions for Investors

• Long SY shares (12–18 month horizon): target +60% if clinic-level EBITDA expands 300–500bps and national rollout hits 15–20% of planned centers; set tactical stop-loss at -20% and trim on any >30% gap up. Rationale: capture consolidation re-rating while downside limited by tangible clinic assets and recurring service revenue.
• Buy ABBV (AbbVie) 12-month calls or 1H27 targeted long (ticker ABBV): play supplier volume growth from scaled aesthetic chains. Risk: if chains force deeper discounts, supplier pricing power weakens; reward: sustained procedure volume growth should lift supplier FCF. Position size: tactical 2–4% portfolio exposure.
• Relative trade (6–12 months): pair long SY / short China consumer internet discretionary exposure (e.g., KWEB) to express rotation from ad-driven discovery platforms to in-person scaled service providers. Risk: internet platforms can re-accelerate discovery spend; reward: superior unit economics and more durable cashflow from scaled operators.
• Options hedge (3–6 months): buy SY put spreads as downside protection when initiating directionally long exposure — e.g., buy 6-month puts at -15% strike and sell deeper 6-month puts at -30% strike to cap hedge cost. This limits regulatory or safety-shock tail risk while keeping upside optionality.